1. Academic Validation
  2. ATXN3 deubiquitinates YAP1 to promote tumor growth

ATXN3 deubiquitinates YAP1 to promote tumor growth

  • Am J Cancer Res. 2023 Sep 15;13(9):4222-4234.
Shengnan Wang 1 2 Kun Liu 2 Xiaohua Han 3 Yang Cheng 1 2 Emily Zhao 4 Daniel J Brat 2 Zhaolin Sun 1 Deyu Fang 2
Affiliations

Affiliations

  • 1 College of Basic Medical Sciences, Dalian Medical University Dalian 116044, Liaoning, China.
  • 2 Department of Pathology, Northwestern University Feinberg School of Medicine Chicago, IL 60611, USA.
  • 3 Department of Physiology, School of Basic Medicine, Qingdao University Ningxia Road 308, Qingdao 266071, Shandong, China.
  • 4 Weinberg College of Arts and Sciences, Northwestern University Evanston, IL 60201, USA.
PMID: 37818078
Abstract

The ubiquitin-specific peptidase Ataxin-3 (ATXN3) has emerged as a potential oncogene in a variety of human cancers. However, the molecular mechanisms underlying how ATXN3 achieves its tumorigenic functions remain largely undefined. Herein, we report that targeted deletion of the ATXN3 gene in Cancer cells by the CRISPR-Cas9 system resulted in decreased protein expression of Yes-associated protein 1 (YAP1) without altering its mRNA transcription. Interestingly, genetic ATXN3 suppression selectively inhibited the expression levels of YAP1 target genes including the connective tissue growth factor (CTGF) and cysteine-rich angiogenic inducer 61 (Cyr61), both of which have important functions in cell adhesion, migration, proliferation and angiogenesis. Consequently, ATXN3 suppression resulted in reduced Cancer cell growth and migration, which can also be largely rescued by YAP1 reconstitution. At the molecular level, ATNX3 interacts with the WW domains of YAP1 to protect YAP1 from ubiquitination-mediated degradation. Immunohistology analysis revealed a strong positive correlation between ATXN3 and YAP1 protein expression in human breast and pancreatic cancers. Collectively, our study defines ATXN3 as a previously unknown YAP1 Deubiquitinase in tumorigenesis and provides a rationale for ATXN3 targeting in antitumor chemotherapy.

Keywords

ATXN3; YAP1; cancer; deubiqutinase.

Figures
Products